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comparisons that correspond well with the in vivo nasal potential
difference assay, a mainstay of cystic fibrosis transmembrane
conductance regulator detection in vivo, and have been viewed as
suitable models for testing the activity of CFTR correctors and
potentiators in “personalized medicine” type approaches to cystic
fibrosis (CF) therapeutics [1–3]. Primary nasal septal epithelia
from mice (MNSE) have substantially greater CFTR activity in
Ussing chamber analysis than comparably processed tracheal
monolayers, and allow direct analysis of otherwise genetically
identical (congenic) animals without the confounding effects
attributable to mixed genetic backgrounds [4].
There are three widely utilized F508del transgenic mouse
models—Cftrtm1Kth (Utah), Cftrtm2Cam (Rotterdam), and Cftrtm1Eur
(Cambridge). The Cftrtm1Kth mutated allele contains a 3-bp (CTT)
deletion between bases 1656 and 1660, which results in a loss of a
phenylalanine residue in exon 10 at a position which corresponds
to human position 508 [5]. This exon 10 replacement strategy left a
selective marker gene inserted in one of the introns. This was a
similar strategy to the creation of the Cftrtm2Cam mouse model [6].
This marker gene is likely to have an effect on transcription activity
or mRNA levels of the mutant allele, but does not affect the
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resulted in a mutant exon from which transcriptional activity of the
mutant allele is identical to the normal allele [7]. While the
Cftrtm2Cam mouse was noted to have 1/3 of the transcriptional
activity in all tissues tested, prior studies concerning Cftrtm1Kth
transgenic mice have indicated tissue specific differences in
CFTR expression—specifically lower levels of F508del CFTR
mRNA in the upper intestine compared to wild type animals.
Normal levels of CFTR mRNA were reported previously in
F508del murine lung, testes, and submaxillary glands in the same
strain [5]. Given the high interest in evaluating misprocessing
correctors of F508del CFTR in a relevant in vivo and in vitro
model of disease, proper F508del CFTR expression is critical to
promote maturation of a similar pool of misprocessed protein.
After the University of Alabama at Birmingham Institutional
and Animal Care and Use Committee approval, MNSE tissues
from wild type (C57BL/6), heterozygous F508del, and homozy-
gous F508del/F508del transgenic (Cftrtm1Kth) were cultured on
permeable supports for 14 days to confluence and full differenti-
ation. This F508del mouse strain was obtained from Jackson Labs
(stock # 002515) and backcrossed to the C57BL/6 line 6 times. The
mice are greater than 98% on the BL/6 background. Quantitative
RT-PCR analysis (reported as relative mRNA ± S.D.) showed
dramatic differences in CFTR mRNA among homozygous,
heterozygous, and wild type both in MNSE cultures and tissues
(Fig. 1A). Whether these differences are mediated by higher
expressivity in a pure epithelial cell population (compared tomixed
cells from native tissues), decreased CFTR transcription, or
message instability will require further investigation. In addition,by Elsevier B.V. All rights reserved.
Fig. 1. Relative CFTR mRNA expression in wild type, F508del heterozygous,
and homozygous murine nasal tissues and cell cultures (A). CFTR mRNA
expression in F508del homozygous murine nasal tissues (n = 6 per condition)
and cultures (n = 9 per condition) were significantly reduced (p b 0.05) when
compared to heterozygous (tissue: 2.7 ± 0.3 fold, cell culture: 10.6 ± 3.6) and
wild type (tissue: 5.7 ± 1.2, cell culture: 20.0 ± 8.7). Representative Ussing
chamber tracings of wild type, F508del/F508del, and temperature corrected
(TC) F508del/F508del cell cultures (B). After blockade of epithelial sodium
channels with amiloride (100 μM), temperature corrected cells (24 h at 27 °C
incubation) reveal minimal “corrected” F508del CFTR activity in response to
the adenylyl cyclase agonist forskolin (20 μM). CFTR(inh)172 (10 μM) blocks
CFTR-mediated anion transport.
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following 24 hour low-temperature correction (27 °C) in Ussing
chambers (Fig. 1B).
Our findings suggest significant limitations of nasal airway
cultures from Cftrtm1Kth mice, and previous studies of F508del
CFTR from the tm1 Kth background should be re-evaluated in
this light [8]. For example, potentiator activation profiles
observed in F508del CF mice may underestimate potency as a
result of diminished levels of mRNA in this murine genotype.
While murine CFTR is insensitive to many agents that
enhance the activity of human CFTR (e.g. ivacaftor) [9],
agents (e.g. flavonoids) known to increase channel opening in
both murine and human CFTR should be appraised in this light.
Furthermore, this mouse model should not be utilized for
evaluating F508del misprocessing correctors with upper airway
experiments in vivo (e.g.NPDmeasurements) or in vitro (primary
nasal cell culture electrophysiology) endpoints. The findings alsoprovide a cautionary note indicating the potential for highly
discordant levels of CFTR mRNA from certain CFTR genotypes
should nasal cells be developed as a universal screen meant to
“personalize” CFTR modulation therapy in patients with rare
genetic defects.Research support
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